EP3305285
Andandrógen til meðhöndlunar á krabbameini í blöðruhálskirtli án meinvarpa sem ekki svarar hormónahvarfsmeðferð
Status:
EP Einkaleyfi ógilt eftir andmæliEP appl. date:
23.9.2013EP published:
2.9.2020EP application number:
17187458.9
EP translation filed:
28.10.2020Grant published:
15.11.2020EPO information:
European Patent Register
Max expiry date:
22.9.2033Expiry date:
22.9.2025
Title:
ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC CASTRATE-RESISTANT PROSTATE CANCER
Timeline
Today
23.9.2013EP application
2.9.2020EP Publication
28.10.2020Translation submitted
15.11.2020Registration published
22.9.2025Expires
Owner
Name:
Aragon Pharmaceuticals, Inc.Address:
10990 Wilshire Blvd. Suite 300, Los Angeles, CA 90024, US
Inventor
Name:
CHEN, IsanAddress:
San Diego, CA 92122, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201261705900 PDate:
26.9.2012Country:
US
Classification
Categories:
A61K 31/00, A61K 31/4166, A61K 31/4439, A61P 35/00
Annual fees
Number
Paid
Expires
Payer
Number: 8
Paid: 15.12.2020
Expires: 22.9.2021
Payer: Árnason Faktor ehf.
Number: 9
Paid: 10.8.2021
Expires: 22.9.2022
Payer: Árnason Faktor ehf.
Number: 10
Paid: 16.8.2022
Expires: 22.9.2023
Payer: Árnason Faktor ehf.
Number: 11
Paid: 5.9.2023
Expires: 22.9.2024
Payer: Árnason Faktor ehf.
Number: 12
Paid: 7.8.2024
Expires: 22.9.2025
Payer: Árnason Faktor ehf.